This 2014 retrospective audit evaluated the safety, tolerability, and efficacy of combination phentermine and topiramate therapy for weight maintenance in 103 patients at the Austin Health Weight Control Clinic. Patients initially achieved a 10% weight loss through a very low energy diet (VLED). Among them, 61 discontinued the combination therapy,
This 2013 review evaluates the efficacy and safety of phentermine/topiramate extended-release (PHEN/TPM ER) capsules, marketed as Qsymia, for obesity management. Clinical trials demonstrated significant weight loss ranging from 8.1% to 10.9% with mid to high doses, compared to 1.4% to 1.8% with placebo. PHEN/TPM ER also led to reductions in
This 2003 randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of topiramate (TPM) for weight loss in 385 obese adults aged 18–75. Participants were assigned to receive placebo or TPM at doses of 64, 96, 192, or 384 mg/day, alongside a standardized lifestyle program. After 24 weeks, mean weight
This 56-week, randomized, placebo-controlled trial assessed the efficacy and safety of controlled-release phentermine/topiramate (PHEN/TPM CR) in 1,267 adults with class II or III obesity (BMI ≥35 kg/m²). Participants were randomized to receive placebo, PHEN/TPM CR 3.75/23 mg, or PHEN/TPM CR 15/92 mg, alongside a reduced-calorie diet. At week 56, mean
This 2015 meta-analysis reviewed data from three randomized controlled trials involving 294 patients to assess topiramate’s efficacy and safety in treating essential tremor (ET). The analysis showed that topiramate significantly improved tremor severity, motor function, and reduced functional disability compared to placebo. The mean difference in the Fahn–Tolosa–Marin Tremor Rating
